

## COVID-19 Vaccination Quick Links

Current as of June 8, 2023

ASPR TRACIE created this resource to assist clinicians in quickly finding the most relevant and current information about COVID-19 vaccines available in the United States, their intended populations, recommendations for their use, effectiveness and safety issues, potential adverse events to be aware of, and resources to help communicate with patients. Additional resources are also linked to access more detailed information.

### Vaccines Available in the U.S.\*

#### Pfizer-BioNTech (Comirnaty)

##### FDA Emergency Use Authorization (EUA)—bivalent<sup>#</sup>

- 1 dose of bivalent vaccine for individuals 5 years & older at least 2 months after last monovalent vaccine dose
- 1 dose of bivalent for those ages 6 months to 4 years at least 8 weeks after 2nd dose of monovalent or at least 2 months after 3rd dose of monovalent
- 2 doses of bivalent for those ages 6 months to 4 years who received 1 monovalent dose, with 1st dose at least 3 weeks after monovalent & 2nd dose at least 8 weeks later
- 2nd bivalent dose for individuals 65 years of age & older at least 4 months after 1st bivalent dose
- 2nd bivalent dose for certain immunocompromised individuals 5 years & older at least 2 months after 1st bivalent plus additional doses at healthcare provider's discretion
- 1 dose of bivalent for certain immunocompromised individuals ages 6 months to 4 years of age at least 1 month after 3rd vaccine dose plus additional doses at healthcare provider's discretion
- 1 dose of bivalent for previously unvaccinated individuals 5 years & older
- 3 bivalent doses for previously unvaccinated individuals 6 months to 4 years of age

#### Johnson & Johnson/Janssen \*

##### FDA EUA

- 1 dose in individuals 18 years of age & older
- Booster dose at least 2 months after primary dose for those ages 18 and older

#### Moderna (Spikevax)

##### FDA EUA—bivalent

- 1 dose of bivalent for individuals 6 years & older at least 2 months after last monovalent vaccine dose
- 1 bivalent dose for those ages 6 months to 5 years at least 1 month after single monovalent dose or at least 2 months after 2 monovalent doses
- 2nd bivalent dose for individuals 65 years of age & older at least 4 months after 1st bivalent dose
- 2nd bivalent dose for certain immunocompromised individuals 6 years & older at least 2 months after 1st bivalent dose plus additional doses at healthcare provider's discretion
- 1 dose of bivalent for certain immunocompromised individuals ages 6 months to 5 years at least 1 month after last bivalent dose plus additional doses at healthcare provider's discretion
- 1 dose of bivalent for previously unvaccinated individuals 6 years & older
- 2 doses of bivalent for previously unvaccinated individuals 6 months to 5 years of age

#### Novavax

##### FDA EUA








- 2 dose primary series in individuals 12 years of age & older
- Booster dose at least 6 months after primary series for those 18 years of age & older for whom mRNA vaccine is not accessible/clinically appropriate or would not otherwise receive a COVID-19 vaccine

\* On May 10, 2023, CDC [announced](#) that any remaining doses of Johnson & Johnson/Janssen vaccine in the U.S. should be disposed of due to product expiration. As the request of the manufacturer, FDA [revoked](#) the EUA for the Johnson & Johnson/Janssen COVID-19 vaccine on June 1, 2023.

<sup>#</sup> Monovalent mRNA vaccines are no longer authorized in the U.S.

The [recommended timing](#) of the 2nd dose for those who received a Pfizer-BioNTech, Moderna, or Novavax vaccine for their primary series is dependent upon age, sex, risk of severe disease, rates of community transmission, and immunocompromised status.

FDA [authorized](#) heterologous, or mix-and-match, booster doses using any vaccine authorized as a booster. The timing of the booster dose and eligible population are based on the vaccine used for the primary series.

 <b>Recommendations</b>	
<a href="#">Advisory Committee on Immunization Practices (ACIP) COVID-19 Vaccine Recommendations</a> <a href="#">CDC Interim Clinical Considerations for Use of COVID-19 Vaccines in the US</a>	
 <b>SARS-CoV-2 Variants</b> <a href="#">Variants of the Virus</a>  <b>Effectiveness</b> <a href="#">COVID-19 Vaccine Effectiveness</a>  <b>Safety</b> <a href="#">Ensuring COVID-19 Vaccine Safety in the U.S.</a>	 <b>Potential Adverse Events</b> <a href="#">Common Side Effects</a> <a href="#">Anaphylaxis</a> <a href="#">Guillain-Barre Syndrome</a> <a href="#">Myocarditis/Pericarditis</a> <a href="#">Thrombosis with Thrombocytopenia Syndrome</a>
 <b>Communicating with Patients</b>	
<a href="#">Be a COVID-19 Vaccine Champion Webinar</a> <a href="#">Building Confidence in COVID-19 Vaccines</a> <a href="#">Communication Resources for COVID-19 Vaccines</a>	<a href="#">COVID-19 Vaccine for Children</a> <a href="#">Immunization Communications Resource Toolkit</a> <a href="#">Vaccine Communications Tips</a> <a href="#">Vaccine Recipient Education</a>
 <b>Additional Resources</b>	
ASPR TRACIE: <a href="#">COVID-19 Vaccine Resources Collection</a> CDC: <a href="#">Vaccines for COVID-19</a>	FDA: <a href="#">COVID-19 Vaccines</a> NIH: <a href="#">COVID-19 Vaccines</a>